Annual Inventory Summary of Peripheral T-Cell Lymphoma Progress in 2021

Looking back on the past, looking forward to the future
.

On the occasion of the arrival of 2022, Yimaitong Hematology launched the "Annual Inventory" series of articles, summarizing the research fronts worthy of attention in the field of blood diseases in 2021
.

Today, we bring you a summary of "peripheral T-cell lymphoma (PTCL)" related content, click the title of the article to read the original text
.

PTCL is a group of malignant tumors originating from mature T cells.
Compared with B-cell lymphoma, the progress of PTCL treatment is relatively lagging behind
.

Because of its difficult treatment and poor prognosis, it has attracted great attention both at home and abroad
.

What is the current status of diagnosis and treatment of PTCL in China? See what the experts say
.

For details, please refer to: 1.
Interview with a big coffee | Prof.
Dehui Zou: Talking about the current situation and progress of PTCL diagnosis and treatment 2.
Prof.
Bai Ou: Inventory of research progress of peripheral T-cell lymphoma At the 6th Anti-leukemia and Lymphoma International Summit Forum, Prof.
Dehui Zou Conducted the theme report "Clinical characteristics and efficacy analysis of peripheral T-cell lymphoma (PTCL): real-world database analysis of the Institute of Hematology, Chinese Academy of Medical Sciences", indicating that PTCL is highly heterogeneous, and different subtypes have different clinical characteristics, treatment options and prognosis.
There is a big difference in PTCL, and further research on the genetics and molecular pathogenesis of PTCL is needed in the future to explore effective targeted therapy
.

For details, please refer to: Prof.
Dehui Zou: Analysis of Clinical Characteristics and Efficacy of Peripheral T-cell LymphomaProfessor Zhang Liling at the 6th Anti-Leukemia and Lymphoma International Summit Forum with the title of "New Progress and Practice Sharing of Targeted Therapy for Peripheral T-cell Lymphoma", In-depth discussions were conducted in three aspects: "current status of peripheral T-cell lymphoma (PTCL) treatment", "optimization of initial treatment regimens", and "exploration of relapsed and refractory regimens"
.

For details, please see: Prof.
Zhang Liling: New progress and practice sharing of targeted therapy for peripheral T-cell lymphoma In recent years, various new chemotherapeutic drugs and new targeted drugs have emerged, changing the pattern of diagnosis and treatment of PTCL
.

What medicines and treatment options are worth paying attention to? For details, please refer to: Professor Zhu Jun: Progress in the Treatment of Peripheral T-Cell Lymphoma | The 2nd China Hematology Development Conference The 4th China Lymphoma Individualized Therapy Conference and the 2021 Annual Meeting of the Lymphoma Professional Committee of the China Anti-Cancer Association, Zhang Hui Professor Lai shared "New progress in the treatment of peripheral T-cell lymphoma (PTCL) under the guidance of new drugs"
.

For details, please refer to: Professor Zhang Huilai: New Developments in Peripheral T-Cell Lymphoma Treatment Led by New Drugs | The 4th China Lymphoma Individualized Therapy Conference Selinexor (ATG-010) is the world's first approved Oral selective inhibitor of nuclear export protein (SINE), Prof.
Huiqiang Huang shared the case experience of Selinesol in the treatment of relapsed/refractory (R/R) PTCL
.

For details, please refer to: World Lymphoma Day | Prof.
Huiqiang Huang will introduce you to the new progress of Selinesol in the treatment of patients with peripheral T-cell lymphoma, whether it is the first-line treatment of PTCL patients, the second-line treatment of relapsed and refractory PTCL patients, or PTCL not suitable for transplantation Patients, multiple studies have confirmed the efficacy and safety of chemotherapy combined with Chidamide
.

For details, please refer to: 1.
Interview with a big coffee | Prof.
Qingqing Cai talks about the progress of Chidamide combined regimen in the treatment of peripheral T-cell lymphoma 2.
2021 ASH big-time talk about Prof.
Bai Ou takes an inventory of Chidamide in the treatment of peripheral T-cell lymphoma Research progress The research progress of two new drugs, the PI3K inhibitor duvelisib and the JAK1 inhibitor DZD4205, announced at the 2021 ICML conference in the treatment of R/R PTCL
.

For details, please see: 2021 ICML | New Drug Discovery for Relapsed and Refractory Peripheral T-Cell Lymphoma With the discovery of mutations in epigenetic regulators such as TET2, DNMT3A, and IDH2, the idea that PTCL is regulated by epigenetics has gradually gained support
.

The single-drug activity of epigenetic drugs in PTCL also indirectly confirmed the central role of epigenetic regulation in the pathogenesis of PTCL, and the combination of multiple epigenetic drugs in the treatment of PTCL also showed good efficacy
.

For details, please refer to: Oral azacitidine and romidepsin combination regimen showed good efficacy in PTCL.
Currently, CHOP regimen or CHOP plus etoposide regimen (CHOEP) followed by autologous hematopoietic stem cell transplantation (AutoSCT) is the most common treatment for young PTCL patients.
preferred treatment options
.

However, some studies have shown that patients with relapsed and refractory PTCL should receive allogeneic hematopoietic stem cell transplantation (AlloSCT)
.

For details, see: Transplant options after first-line induction chemotherapy for PTCL: AutoSCT or AlloSCT? In recent years, arsenic compounds have played an important role in tumor therapy and have been used as standard therapy for certain leukemias, and have also shown potential value in the field of lymphoma therapy
.

For details, please refer to: 1.
Attacking cancer with "poison"Innovative organic arsenic anticancer therapy for malignant lymphoma is worth looking forward to 2.
2021 ASH first lookMultiple Asian countries on Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma Phase 2 research stamp "read the original text", let's make progress together